Dear Editor,Cardiovascular disease is the leading cause of deaths worldwide,with coronary artery disease(CAD)accounting for approximately 50%of its mortality.Dual antiplatelet therapy,including aspirin and a P2Y12 inh...Dear Editor,Cardiovascular disease is the leading cause of deaths worldwide,with coronary artery disease(CAD)accounting for approximately 50%of its mortality.Dual antiplatelet therapy,including aspirin and a P2Y12 inhibitor,is the most important treatment for CAD patients undergoing percutaneous coronary intervention(PCI)to prevent recurrent ischemic events and cardiac death.Clopidogrel is one of the commonly used P2Y12 inhibitors.However,up to 30%of patients treated with a standard dose of clopidogrel present with high on-treatment platelet reactivity(HOPR),which is associated with the increased ischemic risks[1].The causes of HOPR are multifactorial and complex.展开更多
Dear Editor,The coronavirus disease 2019(COVID-19) broke out in early December 2019 in Wuhan, China~([1]), which put tremendous pressure on the medical system. A nationwide lockdown and strict quarantine measures prov...Dear Editor,The coronavirus disease 2019(COVID-19) broke out in early December 2019 in Wuhan, China~([1]), which put tremendous pressure on the medical system. A nationwide lockdown and strict quarantine measures proved effective in reducing the spread of the pandemic. However, it might have affected the management of time-dependent diseases such as STelevation myocardial infarction(STEMI)~([2]).展开更多
基金supported by the National Natural Science Foundation of China(Grant No.82170351)the Jiangsu Province's Key Provincial Talents Program(Grant No.ZDRCA2016013)the Special Fund for Key R&D Plans(Social Development)of Jiangsu Province(Grant No.BE2019754).
文摘Dear Editor,Cardiovascular disease is the leading cause of deaths worldwide,with coronary artery disease(CAD)accounting for approximately 50%of its mortality.Dual antiplatelet therapy,including aspirin and a P2Y12 inhibitor,is the most important treatment for CAD patients undergoing percutaneous coronary intervention(PCI)to prevent recurrent ischemic events and cardiac death.Clopidogrel is one of the commonly used P2Y12 inhibitors.However,up to 30%of patients treated with a standard dose of clopidogrel present with high on-treatment platelet reactivity(HOPR),which is associated with the increased ischemic risks[1].The causes of HOPR are multifactorial and complex.
文摘Dear Editor,The coronavirus disease 2019(COVID-19) broke out in early December 2019 in Wuhan, China~([1]), which put tremendous pressure on the medical system. A nationwide lockdown and strict quarantine measures proved effective in reducing the spread of the pandemic. However, it might have affected the management of time-dependent diseases such as STelevation myocardial infarction(STEMI)~([2]).
